The response rate of anti-PD-1 or anti-CTLA4 immunotherapy in melanoma patients was significantly higher in the low-risk group, while patients in the high-risk group presented a greater sensitivity to chemotherapy. This evidence concerns the gene CTLA4 and melanoma.